CIAM
CRSP icon

Caitong International Asset Management’s CRISPR Therapeutics CRSP Stock Holding History

Caitong International Asset Management’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$59.2K Buy
+1,085
New +$57.2K 0.01% 678
2025
Q3 		– Sell
-1,841
Closed -$89.5K – 2043
2025
Q2 		$89.5K Buy
1,841
+1,750
+1,923% +$67.7K 0.06% 163
2025
Q1 		$3.1K Sell
91
-2,384
-96% -$101K ﹤0.01% 1174
2024
Q4 		$97.4K Buy
+2,475
New +$117K 0.1% 249

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
GP
GSK plc London $602M AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Caitong International Asset Management's CRSP Position: Q2 2026 in Review

Caitong International Asset Management opened a new position in CRISPR Therapeutics (CRSP) in Q2 2026: 1,085 shares worth $59.2K. The stake represents 0.01% of the portfolio and ranks #678 among its holdings. This is a return to the name: Caitong International Asset Management previously reported a position in CRSP as recently as Q2 2025.

Caitong International Asset Management first reported a position in CRSP in Q4 2024 and has held it in 4 quarters since. The position peaked at $97.4K in Q4 2024. 524 funds tracked by Wall St. Rank hold CRSP as of Q2 2026.

  • Caitong International Asset Management held 1,085 shares of CRISPR Therapeutics worth $59.2K as of Q2 2026.
  • CRISPR Therapeutics was a new Caitong International Asset Management position in Q2 2026.
  • CRISPR Therapeutics made up 0.01% of Caitong International Asset Management's portfolio in Q2 2026, its #678 holding.
  • Caitong International Asset Management first reported a position in CRISPR Therapeutics in Q4 2024 and has held it in 4 quarters since.
  • Caitong International Asset Management's CRISPR Therapeutics position peaked at $97.4K in Q4 2024.
  • 524 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q2 2026.

Based on Caitong International Asset Management's 13F filing for Q2 2026, filed 5 Aug 2026.